MedPath

A clinical trial to study the effect of nebulization of Colistin or Amikacin for prevention of ventilator-associated pneumonia in patients requiring ventilatory support in intensive care unit.

Phase 3
Conditions
Health Condition 1: J22- Unspecified acute lower respiratory infection
Registration Number
CTRI/2024/06/068660
Lead Sponsor
Department of Anaesthesiology and Critical Care
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

Patients requiring mechanical ventilation for more than 72 hours.

Exclusion Criteria

Grossly purulent sputum or pneumonia on admission; new and persistent infiltrates on chest radiography within 48 hours from admission.

Severe chronic obstructive pulmonary disease (COPD) or preexisting lung disease requiring long-term inhalation drug therapy.

Long-term therapy with corticosteroids or immunosuppressive drugs, human immunodeficiency virus infection, cancer.

Colonization or infection with a strain resistant to colistin and amikacin on admission.

Acute kidney injury on the day of inclusion. Patients undergoing renal replacement therapy or for whom a decision had been made to initiate renal replacement therapy can be included whatever the KDIGO stage.

Chronic kidney failure.

Pregnancy and breastfeeding women.

Allergy to colistin or amikacin.

Myasthenia gravis.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath